Revance Releases Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Aegis Capital Reiterates Buy on Revance Therapeutics (RVNC) Following 4Q Report
February 28, 2017 8:18 AM ESTAegis Capital reiterated a Buy rating and $28.00 price target on Revance Therapeutic (NASDAQ: RVNC) following the company's 4Q earnings report. Revance reiterated its prior guidance for cash burn of $102 to $112 mil for 2017.
Analyst Difei Yang commented, "Yesterday, Revance Therapeutics announced fourth quarter... More
Revance Therapeutics (RVNC) Misses Q4 EPS by 11c
February 27, 2017 4:14 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.95), $0.11 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.
2017 Financial Outlook
Revance reiterates its financial guidance provided in January 2017. Revance expects cash... More
